Repositioning Candidate Details
| Candidate ID: | R0813 |
| Source ID: | DB05484 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MDX-018 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses. In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice. HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified). |
| DrugBank Pharmacology: | MDX-018 is a fully human anti-inflammatory antibody for the treatment of Autoimmune Disease. The drug inhibits tumour growth by targetting interleukin-8 (IL-8), a major inflammation mediator. It reduces disease activity in palmoplantar pustulosis patients and is also effective in the treatment of glioblastoma, which has a very low survival rate. |
| DrugBank MoA: | he drug inhibits tumour growth by targetting interleukin-8 (IL-8), a major inflammation mediator. |
| Targets: | Interleukin-8 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|